NEW YORK, April 12 – GlaxoSmithKline has agreed to non-exclusively license Valentis’ GeneSwitch gene regulation technology for its functional genomics research, the companies said Thursday.

The licensing agreement for GeneSwitch is the second in two months for Valentis, which first licensed the technology to Wyeth-Ayerst Laboratories in February. The GeneSwitch technology controls the expression of a gene in transgenic animals and cell cultures with a trigger that turns the expression of the gene on or off.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.